What is Supernus Pharmaceuticals's contract liabilities?

Supernus Pharmaceuticals (SUPN) reported contract liabilities of $0 in Q3 2025.

What does contract liabilities mean?

Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.

Supernus Pharmaceuticals SUPN Contract Liabilities

Discontinued — last reported Q3 '25

Contract Liabilities at other companies

Travel + LeisureTNL

$479M-1.6%

Alkami Technology, Inc.ALKT

$25.82M+0.7%

Envista Holdings CorporationNVST

$24.1M+21.1%

VontierVNT

$59.7M+4.0%

Archer AviationACHR

$10M-24.8%

Kiniksa Pharmaceuticals International, plcKNSA

$31.81M0.0%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Supernus Pharmaceuticals’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's contract liabilities?: Supernus Pharmaceuticals (SUPN) reported contract liabilities of $0 in Q3 2025.
What does contract liabilities mean?: Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.